Duncan Rudkin, the CEO of the General Pharmaceutical Council (GPhc) has highlighted the importance of strengthening pharmacy governance to provide clarity
around how pharmacies are organised and managed.
This will ensure that patients and the public continue to receive safe and effective pharmacy care, he said while speaking at the annual Sigma Conference in
London on Sunday (5 November).
According to him, there could be rules that outlined the essential roles and responsibilities of responsible pharmacists, and professional standards for
responsible pharmacists, superintended pharmacists and chief pharmacists.
He also announced that the GPhC will be shortly launching a consultation to integrate a new set of standards for the statutory role of hospital chief
pharmacists "which up until recently has never been recognised in law." It is expected to be launched by early January 2024.
However, Duncan, emphasised that they cannot start the work on standards for responsible and superintendent pharmacists until they know the government plans
in relation to supervision.
"Because of course, the responsible pharmacists' regime, and the supervision regime are in many ways intertwined, and can't certainly be looked at separately.
The Royal Pharmaceutical Society (RPS) has said that multi-buy deals on paracetamol violate the existing voluntary sales guidelines.
The professional body is urging the government to pass legislation that prohibits retailers from making such offers on medicines for pain relief.
They have also sent letters to MP Maria Caulfield who is the Minister for Mental Health and Women's Health.
The Medicines and Healthcare Products Regulatory Agency (MHRA) is requesting to take action on the legislation at the earliest.
The concern raised is that multi-buy offers such as 'buy one get one free' can encourage people to buy and store excess packs, which may lead to accidental
or impulsive overdose.
Pharmaceutical Services Negotiating Committee (PSNC) has expressed its support for alterations in the Human Medicines Regulations 2012 to enable original pack dispensing (OPD) and supply of medicines containing sodium valproate by pharmacists.
PSNC's support for changes was in response to the consultation on OPD, initiated by the Department of Health and Social Care (DHSC).
The consultation had proposed regulatory changes to allow pharmacists to dispense (up to 10 per cent) more or less than the prescribed quantity of a given medicine in the manufacturer's original packs.
Key aims of the proposal are to "support increased patient safety by ensuring patients receive the necessary information that is included in the original manufacturer's packaging about the safe and effective use of a product," DHSC said.
The Royal Pharmaceutical Society (RPS) has secured a contract with the National Institute for Health Research (NIHR) to deliver a suite of e-learning modules to help pharmacy professionals "become more research active".
The new online resources - due to be launched next summer - are aimed at pharmacists and pharmacy technicians who may not have followed an academic career path or have had little or no experience of research delivery. The e-learning package will allow them to gain new skills so they feel more confident to engage with research and research opportunities.
Nine modules are being developed covering how to transform ideas into a research project, find and evaluate evidence and choose the appropriate research methods
whilst learning how to apply for research funding and deal with governance issues and publication.
The Pharmacists' Defence Association has reported an increase in the number of pharmacists calling its advice line to inform about the incidences of violence and intimidation from protesters opposing the Covid-19 vaccination programme.
The association noted that such incidents have become more common with protesters "gaining entry to premises in groups and trying to disrupt Covid-19 vaccinations from taking place."
In many cases, pharmacists, staff, and members of the public have been subjected to verbal threats, causing distress and anxiety among those working to deliver the vaccination programme in a safe environment.
The PDA reminded that employers, having a contract with the NHS for the Covid-19 vaccinations, have a duty to keep their staff safe whilst at work.
The General Pharmaceutical Council (GPhC) standards for pharmacy premises also carry a duty to ensure the safety of staff and the public receiving services on those premises.
Alitam Group, the 100-plus pharmacy store consolidation, has appointed Bharti Patel, the former group executive director of Avicenna to its executive board.
Patel, who was part of the leadership team at Avicenna until late 2021, brings with her a wealth of experience covering pharmaceuticals, multiple retail and independent pharmacy, homecare and NHS primary and secondary care.
In her early career, she worked at Lloyds Pharmacy, where she rose from a prescription medicines buyer to director of procurement over a period of eight years.
She is known in the industry for her strong leadership, commercial acumen and ability to create opportunities for innovation and strategic partnerships.
Alitam founder and CEO Feisal Nahaboo said in a statement that Patel's appointment will further strengthen the group's ability to deliver its transformative multi-billion-pound 'Pharmacy of the Future' concept.
The Royal Pharmaceutical Society has appointed communications agency to lead a review into how it can develop and strengthen member participation.
"We've appointed communications consultancy Luther Pendragon to carry out an independent review of the participation of members and of our communications
concerning decisions we take on behalf of the profession through our Governance boards," the Society said in a statement on Tuesday (May 10).
It added that review would examine how RPS members, elected members and stakeholders can feel engaged, informed and empowered to influence decisions about RPS policy and understand why decisions around organisational policy have been taken on their behalf by elected representatives.
It will also ensure RPS decision-making processes are open and transparent with an emphasis on evidence-based decision making, and recommend ways elected members are enabled to be publicly accountable for decisions taken by the organisation at Board and Assembly level.
The Royal Pharmaceutical Society (RPS) has called its member to to express their views and fill out the Department of Health and Social Care's hub and
spoke survey on the proposed model of dispensing.
The Society has urged its members to fill out the survey before May 20.
RPS president Claire Anderson said: "It is vital that RPS members have their say on issue that impact you in your roles. Currently only single legal entities
can make use of this model of dispensing.
"Our survey, which opened today, seeks your views and comments and will help to inform the RPS submission to this consultation."
The consultation on the proposals to enable all community pharmacies to access hub and spoke dispensing published by the Department of Health and Social Care
(DHSC) will run for three months and will close on June 8, 2022.
The General Pharmaceutical Council (GPhC) has called for comments and views on the recently launched consultation on selecting the appropriate mode of consultation when assessing a person's needs by pharmacy professionals including pharmacist prescribers.
The guidance note sets out what the pharmacy professional or prescriber, in
agreement with the patient, needs to consider when selecting the mode of consultation - such as face-to-face; video-link, video-chat, or other online platforms;
telephone and online questionnaires - best suited to gaining the information needed to deliver safe and effective pharmacy care.
The principles outlined in the guidance apply to consultations undertaken in all pharmacy settings, including those undertaken by online pharmacy services providers.
"Our plan is to include the contents of this guidance note in the document: 'In practice: Guidance for pharmacist prescribers' when we undertake our next review," said the regulator.
The voter turnout in England for the Royal Pharmaceutical Society's English Pharmacy Board election dropped to 7.9 per cent this year.
Out of a total of 19,512 eligible individuals, only 1,534 decided to vote.
The RPS English Board received ten nominations for five vacancies this year; therefore an election was conducted. One nomination was received for the three
vacancies on the Welsh Pharmacy Board. Three nominations were received for the three vacancies on the Scottish Pharmacy Board. Therefore, no election was
conducted in pharmacy boards in Wales or Scotland.
RPS president Claire Anderson said: "It's disappointing that the voter turnout in England has dropped to 7.9 from 11.8 per cent in 2021. We have now appointed
an independent review of how RPS members, elected members and stakeholders can feel more engaged and empowered to influence RPS decisions, and eagerly await
its recommendations."
The Society appointed communications agency Luther Pendragon to lead a review into how it can develop and strengthen member participation.
The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections.
Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients.
NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be
given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection.
Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan.
"Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.
Department of Health of Social Care (DHSC) has confirmed that the Dexcom One Transmitter will be added to Part IXA of the March 2023 Drug Tariff.
"Previously, patients were advised to obtain the free-of-charge Dexcom One transmitters directly from the pharmacies, without a prescription, as the original
Drug Tariff application for the transmitter was unsuccessful," said the Pharmaceutical Services Negotiating Committee (PSNC)
It has raised concerns with DHSC and Dexcom that these distribution arrangements for transmitters are unacceptable because they result in extra unfunded activity
for community pharmacies.
Both, DHSC and Dexcom acted upon these concerns by agreeing to add the Dexcom One transmitter to the Drug Tariff from March 2023. At the same time, Dexcom One CGM
System (containing 1 sensor, 1 sensor applicator, 1 transmitter) will also be added to the March Drug Tariff.
The Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns over the NHS ad campaign highlighting how community pharmacies can support patients
with non-health advice amidst the growing pressure on pharmacies.
It believes the campaign will only 'worsen' the pressure on pharmacies.
"It is always deeply concerning to see campaigns directing people to pharmacies without any regard for the pressures they are under: it is irresponsible and extremely
unhelpful," said PSNC Chief Executive Janet Morrison.
She called the campaign 'particularly irritating' just weeks after the committee rejected a series of proposals from NHS England and DHSC on relief measures to ease
pressure on pharmacies as being totally inadequate.
"NHS England Board Members have noted the pressure on pharmacies - so why are their teams so often acting to make these pressures worse? We need to see a radical
change in how NHS England treats pharmacies and we're continuing to press for that via our influencing and campaigning work," she added.
The NHS launched the new campaign on Monday (27 February) to highlight how high-street pharmacies can support patients with non-urgent health advice for minor
conditions including coughs, aches and colds.
Community pharmacies in Cornwall have delivered more than 8000 face-to-face consultations over last 12 months.
Walk In Consultation Service (WICS) began 12 months ago when pharmacies in Cornwall started offering face-to-face consultations for a wide range of minor ailments,
and NHS treatment as required - the first service of its kind in England.
Cornwall & Isles of Scilly Scilly Local Pharmaceutical Committee (LPC) Chief Officer Nick Kaye joined Operations Manager Drew Creek in Parliament recently by invite
of Steve Double MP, St Austell and Newquay to meet with Minister for Health Neil O'Brien MP to present the service to them and Senior Civil Servants from DHSC and
NHSE with a view to rolling this service out nationally.
The data from these consultations show that over 6000 GP appointments were averted as a result of the service being available. After each consultation a record was
sent to the patient's GP for information.
The Pharmaceutical Services Negotiating Committee (PSNC) has published a guidance for community pharmacies to help them in the implementation of the new
Prescription Prepayment Certificate (PPC) for hormone replacement therapy (HRT).
The new policy will rollout from 1 April 2023, patients who are not already exempt from NHS prescription charges will be able to purchase an annual HRT PPC for the
cost of two single prescription charges
Major concern raised by PSNC is that the NHS systems have not kept pace with policy, as the certificate is launching without the IT in place to support it.
PSNC has been clear that this is totally unacceptable, including raising this with Ministers directly and warning them that introducing the PPC without this
infrastructure risks causing confusion for some patients and adding to the burden for pharmacy teams.
"Government recognises the challenges but is determined to move forwards with the policy, said the committee. "DHSC has recognised the impact this will have on
pharmacies and we are still pressing for appropriate financial compensation. We have also sought guidance for GPs, and now published our own guidance to try to
make the launch go as smoothly as it can for pharmacy teams."
The Royal Pharmaceutical Society (RPS) has welcomed the appointment of Michael Matheson MSP as Cabinet Secretary for NHS Recovery, Health and Social Care in
Scotland.
Commenting on the announcement Laura Wilson, Director of RPS Scotland, said: "I would like to congratulate Michael Matheson on being appointed to this position.
NHS recovery is vitally important, and pharmacy has a huge amount to offer this agenda.
"Our current priorities include enabling pharmacists to take leadership of prescribing in all care settings, tackling health inequalities and advocating for change,
implementing shared patient records between healthcare professionals to provide high-quality, person centred and safe patient care, improving pharmacists' wellbeing
and tackling the climate emergency by encouraging sustainable and green prescribing across Scotland.
The new Flat Fee payment to roll out in April 2023 to all pharmacy contractors who dispense at least 101 items a month, up to a national total of £70m on an
annual basis.
"The value of the Flat Fee payment has now been determined at £533 per month and will be introduced in the April 2023 Drug Tariff," said the Pharmaceutical Services
Negotiating Committee (PSNC).
"As with all payments, the Flat Fee payments are subject to change throughout the year depending on the overall level of funding delivery to Community Pharmacies.
This will be carefully monitored by PSNC and DHSC, and any funding changes will be communicated to pharmacy contractors as soon as they are known," said PSNC.
he Healthcare Distribution Association (HDA) and the Pharmaceutical Services Negotiation Committee (PSNC) have urged the NHS England and the Department of
Health and Social Care (DHSC) to issue urgent communications requesting that all those involved in medicines supply do not hoard, stockpile or over-prescribe Strep
A antibiotics.
In a statement HDA said that the sudden spike in demand for antibiotics used for the treatment of Strep A has meant that there is not enough of these medicines in
the supply chain currently to meet this increased demand. As a result, wholesalers are working extremely hard with manufacturers to increase the supply of antibiotics.
It added: "As regards pricing, the prices charged to pharmacies by HDA wholesale distributors will directly reflect the increase in prices wholesalers are having
to pay for these medicines from manufacturers at the moment, in order to be able to continue supplying these medicines to pharmacies. This will be the case until
supply and demand are more in sync."
Two Indian pharmaceutical companies, Cipla and Glenmark, are pulling back certain products from the American market due to manufacturing concerns, according
to the US Food and Drug Administration (USFDA).
A New Jersey-based subsidiary of Cipla is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution due to "short fill", news agency
PTI reported, quoting the latest Enforcement Report issued by the US health regulator.
Produced at the company's Indore SEZ plant, this medication is used to manage symptoms associated with lung diseases, such as asthma, chronic bronchitis and
emphysema.
Cipla USA decided to recall the affected lot following complaints of less fill volume in respule and few drops of liquid observed in the intact pouch, the USFDA
said, adding that the drug maker initiated the Class II recall in the US market on March 26 this year.
Pharmacies across Northern Ireland are in financial turmoil, reporting that they are dispensing prescription medicines at a loss due to inadequate
reimbursement from the Department of Health (DoH).
This crisis has led to the closure of almost a dozen pharmacies over the past 18 months, with many others struggling to stay open.
Siobhan McNulty, who runs Melvin Pharmacy in Garrison, County Fermanagh, described the dire situation. "We're dispensing medicines at a loss," she said.
"The reimbursement rates don't match the cost of the drugs, and we're left to cover the gap."
McNulty relies on sales of non-pharmaceutical products to keep her business running.